• Mashup Score: 0

    LONDON — Longitudinal serum alanine aminotransferase trajectories remained stable over time among a subset of patients with nonalcoholic fatty liver disease, according to research presented at the International Liver Congress. In a Healio exclusive interview, Arun J. Sanyal, MBBS, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health, interim chair of the

    Tweet Tweets with this article
    • Longitudinal serum alanine aminotransferase trajectories remained stable over time among a subset of patients with #NAFLD, according to research presented at #ILC2022 @EASLnews #MedTwitter #Hepatology #GITwitter https://t.co/56cKigP69D

  • Mashup Score: 1

    Data from an ongoing study in patients with compensated cirrhosis and clinically significant portal hypertension have raised hope for an emerging treatment option in this rare, deadly disease.

    Tweet Tweets with this article
    • Bulevirtide significantly reduces the load of HDV and is safe in difficult-to-treat patients with compensated #cirrhosis and clinically significant portal #hypertension. https://t.co/RO8tfq4UfR #LiverTwitter #ILC2022

  • Mashup Score: 0

    In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis. At the 2022 International Liver Congress, Terns conducted five oral and poster presentations on data from three programs, including TERN-501, which recently was evaluated in the

    Tweet Tweets with this article
    • “We're very excited to continue the momentum of our clinical development programs as well as being able to build upon our pipeline not only in #NASH but also in #obesity and #cancer,” Diana Chung of @TernsPharma told Healio. #ILC2022 @EASLnews #MedTwitter https://t.co/Ba0GenVf0q

  • Mashup Score: 0

    LONDON — Lower fatigue scores at baseline correlated with adverse clinical events among patients with advanced nonalcoholic steatohepatitis, according to research presented at the International Liver Congress.“Fatigue is very common in patients with NAFLD. In other diseases, fatigue is associated with adverse outcomes, including higher mortality,” Zobair M. Younossi, MD, MPH,

    Tweet Tweets with this article
    • #ICYMI: “Among patients with #NAFLD, those with significant #fatigue not only will suffer from impairment of #qualityoflife but also potentially have worse clinical prognosis," Zobair Younossi, MD, of @InovaHealth told Healio. #ILC2022 @EASLnews https://t.co/vbmKdmuqY5

  • Mashup Score: 2

    LONDON — Cirrhosis severity, infections and mortality outcomes were worse for patients in low to middle-income countries, due in part to poor access to liver transplant and ICU facilities, according to data presented here. “We have health care disparities as well as differing populations and diseases that cause cirrhosis around the world,” Jasmohan S. Bajaj, MD, associate

    Tweet Tweets with this article
    • #ICYMI from #ILC2022: ‘One size does not fit all’: #Cirrhosis care access, #mortality vary widely worldwide @JasmohanBajaj @EASLnews #MedTwitter #Hepatology #GITwitter https://t.co/ZKhmVteggB

  • Mashup Score: 1

    LONDON — Resmetirom was safe and well tolerated at 100 mg and 80 mg doses in patients with nonalcoholic steatohepatitis, according to late-breaking research presented at the International Liver Congress. “The primary and key secondary endpoints from the study were achieved,” Stephen Harrison, MD, medical director for Pinnacle Clinical Research in San Antonio and visiting

    Tweet Tweets with this article
    • “#Resmetirom was safe and well tolerated and provided significant reductions in #liver #fat, low-density lipoprotein cholesterol and other atherogenic lipids vs. placebo," Stephen Harrison, MD, told Healio. #ILC2022 @EASLnews #MedTwitter https://t.co/G0O6DWN52c

  • Mashup Score: 1

    In a Healio video exclusive, Diana Chung, chief development officer at Terns Pharmaceuticals, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with nonalcoholic steatohepatitis. At the 2022 International Liver Congress, Terns conducted five oral and poster presentations on data from three programs, including TERN-501, which recently was evaluated in the

    Tweet Tweets with this article
    • In a Healio video exclusive, Diana Chung, chief development officer @TernsPharma, highlights data on TERN-501, a thyroid hormone receptor beta-agonist for patients with #NASH. #ILC2022 @EASLnews #MedTwitter https://t.co/Ba0GenVf0q